CC
IOVA icon

Commodore Capital’s Iovance Biotherapeutics IOVA Stock Holding History

Commodore Capital’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-362,869
Closed -$8.95M – 28
2021
Q3 		$8.95M Buy
+362,869
New +$8.55M 2.36% 16

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Commodore Capital's IOVA Position: Q4 2021 in Review

Commodore Capital sold out of Iovance Biotherapeutics (IOVA) in Q4 2021, closing a stake of 362,869 shares — an estimated $8.95M sold.

Commodore Capital first reported a position in IOVA in Q3 2021 and held it in 1 quarter. The position peaked at $8.95M in Q3 2021. 246 funds tracked by Wall St. Rank hold IOVA as of Q4 2021.

  • Commodore Capital reported no remaining Iovance Biotherapeutics position as of Q4 2021 after selling out during the quarter.
  • Commodore Capital sold 362,869 Iovance Biotherapeutics shares in Q4 2021, an estimated $8.95M.
  • Commodore Capital first reported a position in Iovance Biotherapeutics in Q3 2021 and held it in 1 quarter.
  • Commodore Capital's Iovance Biotherapeutics position peaked at $8.95M in Q3 2021.
  • 246 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q4 2021.

Based on Commodore Capital's 13F filing for Q4 2021, filed 14 Feb 2022.